Pfizer Clostridioides difficile (C. difficile) Research Collaboration Grant

The Pfizer Clostridioides difficile Research Collaboration aims to engage innovative researchers to explore the burden of C. difficile infections. Selected investigators will collaborate with Pfizer's medical team to design a research project and publication. The initiative covers multiple countries, including France and the US, acknowledging the significant health risks posed by C. difficile. Projects can request funding up to $500,000 USD, with a maximum duration of 12 months, emphasizing the urgent need for further studies in this area.

Overview
This Request for Proposals (RFP) seeks to identify investigators with innovative research proposals who are interested in partnering with Pfizer and potentially other likeminded investigators on co-developing research studies focused on understanding the burden of Clostridioides difficile (C. difficile) infections in humans. Researchers selected from this RFP will work in collaboration with the Pfizer medical team to co-develop a research project, study protocol, and publication in peer-reviewed medical literature. In all selected studies the investigator will serve as the principle investigator and the regulatory sponsor of the study.
Project Types and Area of Interest
C.difficile is a gram-positive, anaerobic, spore-forming, toxin-producing bacillus found in the intestines of humans and animals, as well as in the environment. The production of C.difficile toxin in the intestinal tract results in a diarrheal illness defined as C.difficile infection (CDI). Severe CDI can result in pseudomembranous colitis, toxic megacolon, and even death.
CDI is a significant concern for patients in healthcare settings and communities worldwide [1,2]. In developed countries, CDI is the most common cause of healthcareassociated diarrhea [3]. In the US, the Centers for Disease Control and Prevention (CDC) has estimated that >400,000 persons develop CDI each year resulting in thousands of deaths [4]. Further studies aimed at estimating the CDI disease burden are needed.
The intent of this RFP is to identify and collaborate with investigators to conduct studies to estimate the CDI disease burden. Investigators may pursue a single research study with multiple sites if all parties agree. This RFP will be a two-step process. The first step will be for investigators to submit a Letter of Intent (LOI) providing a high-level synopsis of the proposed project. In the second step, LOIs will be selected for further development into a potential non-interventional research collaboration with Pfizer.
Funding Range and Project Length
Individual projects requesting up to $500,000 USD will be considered.Maximum project length is 12 months.